



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

# Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency

---

Current activities and next steps

3rd PhV industry platform meeting - 13 March 2015



Sabine Brosch, Monitoring and Incident Management Service, Pharmacovigilance Department

An agency of the European Union





# Overview

- I. Legal background
- II. Expected benefits
- III. Detailed guide
- IV. EudraVigilance functionalities – how will it work
- V. Change management



# I. Legal background (1)

Article 27 of Regulation (EC) 726/2004:

- 1.The Agency shall **monitor selected medical literature** for **reports of suspected adverse reactions** to medicinal products containing certain active substances. It shall **publish the list of active substances being monitored** and the medical literature subject to this monitoring.
- 2.The Agency shall enter into the **Eudravigilance** database relevant information from the selected medical literature.
- 3.The Agency shall, in consultation with the Commission, Member States and interested parties, draw up a **detailed guide** regarding the monitoring of medical literature and the entry of relevant information into the Eudravigilance database.



# I. Legal background (2)

Article 107(3) of Directive 2001/83/EC:

.....

For medicinal products containing the active substances referred to in the list of publications monitored by the Agency pursuant to Article 27 of Regulation (EC) No 726/2004, **marketing authorisation holders** shall not be required to report to the Eudravigilance database the suspected adverse reactions recorded in the listed medical literature, but they **shall monitor all other medical literature and report any suspected adverse reactions.**






## II. Expected benefits (1)

- Enhance the **efficiency** of adverse reactions reporting
- Provide a **simplification** for pharmaceutical industry
- **Improve data quality** by reducing the number of duplicates
- Contribute to **resource savings**
- **Support signal detection** activities by NCAs and MAHs

## III. Detailed Guide



Consolidated list of comments  
EMA/716877/2014

- *Released for public consultation from 5 June – 27 July 2014*

### **2015**

- Consolidated comments circulated to PMG 1 at their TC on 16 January
- EV-EWG review of key comments at their meeting on 4-5 February
- Draft MLM guide updated and circulated to PMG 1 on 6 February
- Draft MLM guide finalised with PMG 1 at their TC on 13 February
- Draft MLM guide circulated for comments to PRAC on 13 February
- Draft MLM guide circulated to the EC for comments on 13 February
- Draft MLM guide presented to the IG at their TC on 18 February
- Draft MLM guide discussed at PRAC ORGAM TC 26 February
- Draft MLM guide adopted by PRAC by written procedure on 3 March
- Draft MLM guide endorsed by ERMS-FG on 6 March



## III. Detailed Guide - Scope

### Definition of active substances

- Selection based on Article 57(2) submissions by MAHs
- Centred around high number of marketing authorisations in EEA

### Definition of scientific and medical Literature

- Journal coverage based on three literature reference databases
  - Large, comprehensive and widely used, daily updated and indexed biomedical reference database covering literature from EEA and non-EEA countries
  - A monthly updated database with specialised literature coverage including pharmaceuticals, medical and health related literature and herbals
  - A monthly updated database on complementary medicine and alternative treatments with mainly European coverage





## III. Detailed Guide – Business process description


### Process definition

- Definition of search strategy
- Performance of scientific and medical literature search
- Screening, review and assessment of scientific and medical literature
- Processing of ICSRs (potential and confirmed ICSRs)
- Follow-up
- Recording of activities
- Quality management
- Interaction with stakeholders – service desk





## IV. EudraVigilance functionalities - How will it work?





## IV. EudraVigilance functionalities - How will it work?

1. ICSRs resulting from the MLM service refer to the selected medical literature subject to the monitoring by the Agency and the identified reports of suspected adverse reactions to medicinal products containing active substances identified as part of the scope of the Agency's activities
2. ICSRs resulting from the MLM service are transmitted electronically via the EudraVigilance Gateway to NCAs in EEA Member States in accordance with the reporting requirements of ICSRs applicable during the interim period
3. ICSRs resulting from the MLM service are transmitted electronically to EudraVigilance



## IV. EudraVigilance functionalities - How will it work?

4. ICSRs resulting from the MLM service are made available for download by the MAHs concerned (EudraVigilance download area or EVWEB). This refers to ICSRs of suspected serious adverse reactions occurring within and outside the EEA and non-serious adverse reactions from within the EEA
5. Concerned MAHs can download the ICSRs resulting from the MLM service in XML format in compliance with the “Note for guidance: EudraVigilance Human – Processing of safety messages and individual case safety reports (ICSRs)” (EMA/H/20665/04/Final Rev. 2)

# IV. EudraVigilance functionalities - How will it work?




- EV Services**
- ▶ EVWEB
  - ▶ xEVMPD Export
  - ▶ xEVMPD Bulk update
  - ▶ EV Post

- EV Registered Partners**
- ▶ Manage your profile
  - ▶ QPPV List
  - ▶ Organisations List

- Medical Literature Monitoring**
- ▶ MLM Search result
  - ▶ MLM ICSRs
  - ▶ Archive
  - ▶ ICSR Export

Welcome to the restricted area of the EudraVigilance website  
 To continue, please select one of the available functionalities from the menus on the left of the screen



- Medical Literature Monitoring**
- ▶ MLM Search result
  - ▶ MLM ICSRs
  - ▶ Archive
  - ▶ ICSR Export



# IV. EudraVigilance functionalities - How will it work?



## Eudravigilance ICHICSR Export Manager

Click the filter name to display / hide the filter.  
The Filter Name is highlighted once a selection is made.  
The selection will be filtered-on only when it is highlighted in the list.

[Save Filters](#)  
[Load Filters](#)

pdassep (AAA)  
HUMAN PRODUCTION V. 7.11.5.1

<b>Filters</b>		<a href="#">Copy</a> <a href="#">New</a> <a href="#">Delete</a>
<b>Active Substance Group</b>	paracetamol*	<a href="#">Refresh</a> <a href="#">Clear</a>
Substance Group (one or more Substance Combinations) referenced in Safety Reports. You may make multiple selection in this list.	PARACETAMOL	Order: <input type="checkbox"/> Text
<b>Active Substance Combination</b>	Paracetamol*	<a href="#">Copy</a> <a href="#">New</a> <a href="#">Delete</a>
Substance Combination referenced in Safety Reports. You may make multiple selection in this list.	PARACETAMOL, CAFFEINE PARACETAMOL, CAFFEINE CITRATE PARACETAMOL, CAFFEINE CITRATE, ASPIRIN PARACETAMOL, CAFFEINE MONOHYDRATE PARACETAMOL, CAFFEINE, ACETYL SALICYLIC ACID	<a href="#">Refresh</a> <a href="#">Clear</a>
<b>Start Date (Mandatory)</b>	2015-02-25	<a href="#">Clear</a>
Official Receive Date (Date the ICSRs were entered into EV)		
<b>End Date (Mandatory)</b>	2015-03-12	<a href="#">Clear</a>
Official Receive Date (Date the ICSRs were entered into EV)		
<b>Country of Occurrence</b>		
<b>Active Filters</b>	Click on the Name of the Filter to disable/enable it.	<b>Start Date End Date</b>
Request Name <input type="text"/>	<input checked="" type="radio"/> Initial <input type="radio"/> Case	<a href="#">Count</a> Count <a href="#">Request</a> <a href="#">Refresh List</a>
<b>Request Name</b>	<b>Size</b>	<b>Status</b>
Paracetamol (on 12/03/2015 08:09), ICHICSR	5 (0 done)	In Progress: momentarily <a href="#">Cancel</a>



## IV. EudraVigilance functionalities - How will it work?

**Active Filters** Click on the Name of the Filter to disable/enable it. **Start Date End Date**

Request Name   Initial  Case  59

Queued: about half a Minute

Request Name	Size	Status	
Requested on 12/03/2015 08:15, ICHICSR	59	Queued: about half a Minute	<input type="button" value="Cancel"/>
Requested on 06/03/2015 10:16, ICHICSR	280 (822 KB)	Completed	<input type="button" value="Download"/> <input type="button" value="Archive"/>
Requested on 04/03/2015 17:10, ICHICSR	16 (75 KB)	Completed	<input type="button" value="Download"/> <input type="button" value="Archive"/>
Requested on 04/03/2015 10:28, ICHICSR	1 (5 KB)	Completed	<input type="button" value="Download"/> <input type="button" value="Archive"/>
Requested on 27/02/2015 11:24, ICHICSR	2157 (7.7 MB)	Completed	<input type="button" value="Download"/> <input type="button" value="Archive"/>
15-23jandosagefrm (on 27/02/2015 10:23), ICHICSR	6 (3 KB)	Completed	<input type="button" value="Download"/> <input type="button" value="Archive"/>




## V. Change Management - Technical Preparations

- **MAH WEB Trader user**
  - Access to EVWEB environment: no changes for users registered in the EVWEB environment
  - The existent requirements and browser restrictions for EVWEB apply (preferable IE 8)
- **EudraVigilance download area for MAHs**
  - Test and production environment :
    - ✓ System configured to accept ICSRs with the **Sender identifier** **“MLMSERVICE”**



## V. Change Management – Processes to be discontinued





## V. Change Management – Processes to be discontinued

6. Member States should not re-submit the ICSRs resulting from the MLM service to EudraVigilance.
6. Member States should no longer forward/provide the ICSRs resulting from the MLM service to the concerned MAHs, since MAHs can download those ICSRs from the EudraVigilance Download Area
7. Concerned MAHs should not re-submit the ICSRs resulting from the MLM service to EudraVigilance (suspected serious adverse reactions from outside the EEA)
7. Concerned MAHs should no longer forward/provide the ICSRs resulting from the MLM service to the concerned NCA(s) in the EEA



### III. Change Management – Next steps

- Launch of MLM dedicated webpage at Agency's corporate website
  - Publication of Detailed guide, substances and literature included in the service
- Training on MLM processes and related EudraVigilance functionalities (webinar)
- Testing of new EudraVigilance related functionalities with identified testers (NCAs/MAHs)
  - Agency will contact associations to identify testers from industry (in addition to testers from EV-EWG) and inform about timelines for testing
- Execution of pre-production pilot (two months)
  - Start of operation with a subset of substances
- Full operation of MLM service



# Thank you for your attention

## Further information

---

MLM@ema.europa.eu

### **European Medicines Agency**

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

**Telephone** +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555

**Send a question via our website** [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact)

Follow us on  **@EMA\_News**